Notice of Intent.pdf

PDF 91 KB Posted

Attached to
INTERCEPT Blood System Platelet Processing and ILLUMINATOR Service Maintenance Federal contract opportunity
Solicitation number
HT941025N0005
Issued by
Defense Health Agency

About this file

This document is a Notice of Intent to Sole Source a contract for the INTERCEPT Blood System Platelet Processing and ILLUMINATOR Service Maintenance for the Naval Hospital Guam. The Defense Health Agency Contracting Activity intends to award a firm fixed price contract to Cerus Corporation, the sole source provider of the INTERCEPT Blood System, for platelet processing sets and annual maintenance of ILLUMINATOR equipment. The contract period is a base year from 12/1/2024 to 11/30/2025 with two option years. Cerus Corporation is the only source able to meet the government's needs due to their exclusive licensing agreements and specialized expertise in pathogen reduction technology for blood products. The government is not requesting competitive proposals, but interested parties may submit capability statements by 4 November 2024 to be considered for a potential competitive procurement.

View the file

Other files for this federal contract opportunity

Other files attached to INTERCEPT Blood System Platelet Processing and ILLUMINATOR Service Maintenance, newest first.
File Type Posted
Justification for Non-Competitive Procurement (JNCP)_Redacted.pdf PDF
Statement of Work.pdf PDF

On GovTribe

Work with this file on GovTribe

  • Download the original file
  • Contacts named in this file
  • Similar government files
  • Ask GovTribe AI about this file

Text version

Notice of Intent to Sole Source

HT941025N0005

THIS IS A NOTICE OF INTENT TO AWARD A SOLE SOURCE SUPPLY CONTRACT AND IS NOT A

REQUEST FOR COMPETITIVE QUOTES. The Defense Health Agency Contracting Activity (DHACA), Western Markets Contracting Division (WMCD), San Diego, intends to award a firm fixed price contract for INTERCEPT Platelet Small Volume Processing Set, INTERCEPT Platelet Processing Set with Dual Storage Containers, and Annual Maintenance for Illuminator Serial Numbers V02081701 and V0281702 in support of Blood Bank Department, Naval Hospital Guam in accordance with Federal Acquisition Regulation FAR 13.106-1(b)(1)(i), only one source being available to meet the Government’s needs, to:

Cerus Corporation Unique Entity ID: KJJQRRLY2FL5

CAGE: 1PVJ6

1220 Concord Ave., Ste 600 Concord, CA 94520-4906

Period of Performance:

Base: 12/1/2024 – 11/30/2025 Option 1: 12/1/2025 – 11/30/2026 Option 2: 12/1/2026 – 11/30/2027

Cerus Corporation is a leading biotechnology company specializing in pathogen reduction technology for blood products. Their INTERCEPT Blood System is FDA approved for use with apheresis platelets and whole blood-derived plasma, significantly reducing the risk of transfusion-transmitted infections (TTIs) and sepsis. The system allows for the production of therapeutic platelet doses and plasma units, enhancing blood safety. Cerus Corporation holds exclusive licensing agreements and has a proven track record of providing highly specialized services that are critical for maintaining blood safety standards. Their unique qualifications make them the ideal choice for fulfilling the contract requirements.

This notice of intent is not a request for competitive proposals, and no solicitation document exists for this requirement. Sources interested in responding to this notice are required to submit a capability statement that includes management and technical data and cost information, in sufficient detail and with convincing evidence that clearly demonstrates the capability to provide the required product for United States Naval Hospital Guam.

Capability statements shall not exceed six (8.5 x 11 inch) pages using a font size no smaller than 10-point. All capability statements received by the due date of this notice will be considered by the Government. A request for documentation or additional information or submissions that only ask questions will not be considered as an affirmative response. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement or to proceed with a sole source purchase order.

If a vendor challenges the basis of this requirement, please email capability statements as a Microsoft Word or Adobe PDF attachment to Merlinda M. Labaco at Merlinda.m.labaco.civ@health.mil. The closing date for challenges is no later than 1:00 pm Pacific Daylight Time, 4 November 2024.

NO TELEPHONE REQUESTS/OFFERS WILL BE HONORED

File details come from the government source that posted it. Updated .